Birchview Capital as of June 30, 2022
Portfolio Holdings for Birchview Capital
Birchview Capital holds 64 positions in its portfolio as reported in the June 2022 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Bristol Myers Squibb (BMY) | 40.8 | $56M | 728k | 77.00 | |
Aziyo Biologics (ELUT) | 7.3 | $10M | 1.4M | 7.07 | |
Neurocrine Biosciences (NBIX) | 6.0 | $8.3M | 85k | 97.48 | |
Quidel Corporation | 4.3 | $6.0M | 61k | 97.18 | |
Foghorn Therapeutics (FHTX) | 2.8 | $3.9M | 285k | 13.60 | |
Encana Corporation (OVV) | 2.7 | $3.7M | 84k | 44.19 | |
United Therapeutics Corporation (UTHR) | 2.6 | $3.5M | 15k | 235.67 | |
ACADIA Pharmaceuticals (ACAD) | 2.6 | $3.5M | 249k | 14.09 | |
Biodesix (BDSX) | 2.1 | $2.9M | 1.8M | 1.62 | |
Prothena Corp SHS (PRTA) | 2.0 | $2.8M | 103k | 27.15 | |
Continental Resources | 1.8 | $2.5M | 39k | 65.36 | |
Albireo Pharma | 1.6 | $2.2M | 113k | 19.86 | |
Accelr8 Technology | 1.6 | $2.2M | 2.3M | 0.99 | |
Biohaven Pharmaceutical Holding | 1.6 | $2.2M | 15k | 145.73 | |
Phreesia (PHR) | 1.5 | $2.1M | 83k | 25.01 | |
Masimo Corporation (MASI) | 1.5 | $2.0M | 15k | 130.69 | |
Alkermes SHS (ALKS) | 1.1 | $1.5M | 50k | 29.80 | |
Gossamer Bio (GOSS) | 1.0 | $1.3M | 159k | 8.37 | |
Harrow Health (HROW) | 1.0 | $1.3M | 180k | 7.28 | |
Karyopharm Therapeutics (KPTI) | 0.9 | $1.2M | 269k | 4.51 | |
Corcept Therapeutics Incorporated (CORT) | 0.9 | $1.2M | 50k | 23.78 | |
Cytokinetics (CYTK) | 0.7 | $982k | 25k | 39.28 | |
Aveo Pharmaceuticals | 0.7 | $918k | 140k | 6.56 | |
Pioneer Natural Resources | 0.6 | $848k | 3.8k | 223.16 | |
Equitrans Midstream Corp (ETRN) | 0.6 | $846k | 133k | 6.36 | |
Inhibrx | 0.6 | $800k | 70k | 11.36 | |
2seventy Bio (TSVT) | 0.6 | $790k | 60k | 13.20 | |
Docgo (DCGO) | 0.6 | $785k | 110k | 7.14 | |
Inari Medical Ord (NARI) | 0.5 | $680k | 10k | 68.00 | |
Soleno Therapeutics | 0.5 | $680k | 3.7M | 0.18 | |
ImmunoGen | 0.5 | $675k | 150k | 4.50 | |
Arvinas Ord (ARVN) | 0.5 | $631k | 15k | 42.07 | |
Contrafect | 0.4 | $614k | 200k | 3.07 | |
Turning Point Therapeutics I | 0.4 | $602k | 8.0k | 75.25 | |
Cullinan Oncology (CGEM) | 0.4 | $578k | 45k | 12.81 | |
Apellis Pharmaceuticals (APLS) | 0.4 | $543k | 12k | 45.25 | |
Chemocentryx | 0.4 | $496k | 20k | 24.80 | |
Nektar Therapeutics (NKTR) | 0.4 | $486k | 128k | 3.80 | |
Irhythm Technologies (IRTC) | 0.3 | $432k | 4.0k | 108.00 | |
Amicus Therapeutics (FOLD) | 0.3 | $408k | 38k | 10.74 | |
Bluebird Bio (BLUE) | 0.3 | $406k | 98k | 4.14 | |
Ventyx Biosciences (VTYX) | 0.3 | $404k | 33k | 12.24 | |
Kalvista Pharmaceuticals (KALV) | 0.3 | $394k | 40k | 9.85 | |
Silk Road Medical Inc Common | 0.3 | $364k | 10k | 36.40 | |
Xencor (XNCR) | 0.2 | $337k | 12k | 27.40 | |
Xenon Pharmaceuticals (XENE) | 0.2 | $304k | 10k | 30.40 | |
Protagonist Therapeutics (PTGX) | 0.2 | $301k | 38k | 7.92 | |
Kiniksa Pharmaceuticals | 0.2 | $291k | 30k | 9.70 | |
Zentalis Pharmaceuticals (ZNTL) | 0.2 | $225k | 8.0k | 28.12 | |
BioCryst Pharmaceuticals (BCRX) | 0.2 | $212k | 20k | 10.60 | |
G1 Therapeutics | 0.1 | $198k | 40k | 4.95 | |
Stoke Therapeutics (STOK) | 0.1 | $198k | 15k | 13.20 | |
Iveric Bio | 0.1 | $144k | 15k | 9.60 | |
Inflarx Nv (IFRX) | 0.1 | $102k | 70k | 1.46 | |
Concert Pharmaceuticals I equity | 0.1 | $84k | 20k | 4.20 | |
Angion Biomedica Corp | 0.0 | $62k | 54k | 1.14 | |
Laird Superfood (LSF) | 0.0 | $53k | 28k | 1.89 | |
Aspira Womens Health | 0.0 | $49k | 83k | 0.59 | |
Yield10 Bioscience | 0.0 | $42k | 19k | 2.24 | |
Sientra | 0.0 | $34k | 40k | 0.85 | |
Biogen Idec (BIIB) | 0.0 | $0 | 0 | 0.00 | |
Vanda Pharmaceuticals (VNDA) | 0.0 | $0 | 0 | 0.00 | |
Amarin Corp Spons Adr New (AMRN) | 0.0 | $0 | 0 | 0.00 | |
Akebia Therapeutics (AKBA) | 0.0 | $0 | 0 | 0.00 |